Infliximab Biosimilar Safe, Efficacious for Patients with IBD

In the infliximab reference group, the persistence at month 12 was 94% for Crohn’s disease and 92.8% for ulcerative colitis.

Related Keywords

Paris ,France General ,France ,French ,Yoram Bouhnik , ,Groupe Hospitalier Priv ,Ambroise Par ,Therapeutic Advances ,